about
Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015–16: a modelling studyHIV-1 diversity, transmission dynamics and primary drug resistance in AngolaHighly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic.Rare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in AngolaOn the contribution of Angola to the initial spread of HIV-1.Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamicsDeterminants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.Outbreak of acute respiratory infection among infants in Lisbon, Portugal, caused by human adenovirus serotype 3 and a new 7/3 recombinant strain.Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients.Origin and epidemiological history of HIV-1 CRF14_BG.Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteinsPredictors of attrition and immunological failure in HIV-1 patients on highly active antiretroviral therapy from different healthcare settings in Mozambique.Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors.Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A.Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.Genetic diversity, transmission dynamics, and drug resistance of Mycobacterium tuberculosis in Luanda, Angola.Baseline susceptibility of primary HIV-2 to entry inhibitors.Genetic diversity, transmission dynamics and drug resistance of Mycobacterium tuberculosis in AngolaResistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.Donor-Recipient Identification in Para- and Poly-phyletic Trees Under Alternative HIV-1 Transmission Hypotheses Using Approximate Bayesian Computation.Early infant diagnosis of HIV-1 infection in Luanda, Angola, using a new DNA PCR assay and dried blood spots.Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients.Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides.Amplification of full-length HIV-2 envelope genes.An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity.The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.High genetic diversity of human immunodeficiency virus type 1 in Angola.Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression.Vertical transmission of HIV-2.Detection of HIV1 proviral DNA by PCR and hybridization with digoxigenin labelled probes.Phylogenetic demonstration of two cases of perinatal human immunodeficiency virus type 2 infection diagnosed in adulthood.Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection.Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia.
P50
Q28119353-37D4317F-6D63-47FA-8E2A-EAB30204A4B8Q28542528-D49A66DB-60A1-441E-9002-A23142124935Q30370063-C2F87E46-73F1-4093-8C15-40B4327E0761Q30387160-574F1C9B-D28C-402B-90BC-75A2F031452BQ30391799-53F04F4B-7349-4E8D-AA70-4B7419CF50C2Q33274194-70F86432-1D8D-4EA2-85B3-829F7E528B2BQ33553629-B465324B-4024-4929-B791-3377CCD8DA78Q33591409-4DECFA79-D6DD-46D8-B36B-3278555DF6C2Q33769693-A5B91EB0-A276-4BDB-9E4D-F08143B1E5B3Q33809419-986C919A-C3F6-45EE-9A06-FF0FC69D8AF0Q33966596-731D51DC-235C-43DC-B0E3-407F337E4AC6Q34039423-A01E6112-25C4-43B3-88D0-CB7DECB1EDAAQ34290973-0DF3554E-9399-47B0-ADDC-80395F65BE1CQ34430673-C8034008-67EA-4CE4-B53A-FC6D1DA6FA3EQ35077691-0BE89699-D4DB-4CE7-9E7B-0251788E2DBFQ35156353-C3A292A2-C4A5-4BD3-8878-0E8BB617FC0EQ35983629-5A6E6A75-05E0-4813-9BC6-D95A6F19DDD6Q36525347-E5809512-A671-4367-8D6B-C1DCA0836DB8Q37247746-1ED850D2-3019-4446-A99F-7873043CBA7FQ37448301-BA1D6BEF-8AE0-484C-93BA-6DD8C2BFC408Q37512840-619B7EB7-74CC-4313-AC71-9AD0FF66FA4EQ37517645-7071C80E-C0D6-4748-952D-F6B1D9637C08Q38775511-833623DC-5C2C-46E7-9888-9780DF5E6AF6Q38915512-72CB8666-2706-4589-943F-EEF5B8737C4FQ38946645-BAAA747D-8E7F-4AF2-8A69-C6211BAFB95AQ39213845-0B9BC08A-E66F-46D8-BAFD-D024DE85C6F1Q40040133-4FD645F5-4E1C-455F-856E-B19133025E46Q40120069-033A8A44-7CD9-4974-902F-31637976A79AQ40197811-6D5ED69E-5B7D-4AB9-BB5D-9F7EC84ABD89Q41051936-16DB2B56-9E66-4C1D-B327-A76C038875AEQ41208456-9A42F887-A3F4-4A6C-937D-0A9687D8EC85Q42713370-FC36B18D-89AB-4B3D-9B74-26363EF99AA5Q43143940-CDB7F502-CFF9-4405-8AF5-0DDE167F9E4EQ43425262-1FE055DD-59F4-42C6-B6B4-C719B3A603C1Q43770623-BEB61B06-F89F-4268-AB67-C87930F1C6F8Q44310356-A4DE8F2B-AAB8-49B0-BF08-754DA05411FAQ44707645-D03EC975-1E8A-4C31-9A9E-2541AFE0C707Q45524572-2C5B4F18-06E2-40D2-AE9F-22B0AF290909Q45724156-2191161F-E030-41A0-83AA-29BB033BBB12Q45729269-1D7908D8-9C80-4552-A30E-8DFFAB0AA4AD
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Nuno Taveira
@ast
Nuno Taveira
@en
Nuno Taveira
@es
Nuno Taveira
@nl
Nuno Taveira
@sl
type
label
Nuno Taveira
@ast
Nuno Taveira
@en
Nuno Taveira
@es
Nuno Taveira
@nl
Nuno Taveira
@sl
prefLabel
Nuno Taveira
@ast
Nuno Taveira
@en
Nuno Taveira
@es
Nuno Taveira
@nl
Nuno Taveira
@sl
P214
P1053
A-6252-2014
P106
P1153
6602731390
P21
P214
P2798
P31
P3829
P496
0000-0003-0176-5585
P5008
P734
P735
P7859
viaf-99557943